Targeting UPR has also been reported to be effective in reducing cell survival of mutp53-carrying cancers through the upregulation of the pro-apoptotic UPR molecule CHOP [31], even if the presence of mutp53 may render cancer cells more resistant to such treatment [32]. This evidence concerns the gene DDIT3 and cancer.